Drug Information

Drug (ID: DG00761) and It's Reported Resistant Information

• Name: Ketoprofen
• Synonyms: Ketoprofen; 22071-15-4; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; Orudis; m-Benzoylhydratropic acid; Capisten; Ketoprofene; Profenid; Oruvail; Actron; 3-Benzoylhydratropic acid; Alrheumun; Aneol; Epatec; Orudis (TN); Iso-K; Ketoprofeno; RP-19583; Ketoprophene; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-(m-Benzoylphenyl)propionic acid; Racemic ketoprofen; 3-BENZOYL-ALPHA-METHYLBENZENEACETIC ACID; RU 4733; Ketoprofen (Actron); CHEBI:6128; Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-; Alrheumat; CHEMBL571; Propionic acid, 2-(3-benzoylphenyl)-; (S)-Ketoprofen;Dexketoprofen; 19583 RP; L'Acide (benzoyl-3-phenyl)-2-propionique; MLS000079024; Orudis KT; MFCD00055790; NSC-758144; Kefenid; Ketopron; Menamin; Meprofen; Orugesic; Oscorel; SMR000040181; Fastum; Lertus; Toprec; Toprek; Dexal; DSSTox_CID_771; R.P. 19,583; racemic-Ketoprofen; DSSTox_RID_75783; DSSTox_GSID_20771; 1189508-77-7; Ketoprofenum; RP 19583; Ketoprofene [INN-French]; Ketoprofenum [INN-Latin]; Ketoprofeno [INN-Spanish]; Ketoprofen (+-); (+-)-m-Benzoylhydratropic acid; Benzeneacetic acid, 3-benzoyl-alpha-methyl-; SR-01000075949; Ketorin; rac Ketoprofen; CCRIS 4508; Actron ketoprofen; (rs)-ketoprofen; (+-)-3-Benzoyl-alpha-methylbenzeneacetic acid; (+) ketoprofen; NCGC00016757-01; Ketoprofen ,(S); Acide (benzoyl-3-phenyl)-2-propionique [French]; Prestwick_617; EINECS 244-759-8; 2-[3-(benzoyl)phenyl]propanoic acid; CAS-22071-15-4; Ketoprofen-13C-D3; 2-(3-benzoylphenyl)-propionic acid; Hydratropic acid, m-benzoyl-, (+-)-; Acide (benzoyl-3-phenyl)-2-propionique; Spectrum_001309; Opera_ID_509; Prestwick0_000219; Prestwick1_000219; Prestwick2_000219; Prestwick3_000219; Spectrum2_000956; Spectrum3_001479; Spectrum4_000028; Spectrum5_001254; m-benzoyl-hydratropic acid; Epitope ID:131783; K 1751; SCHEMBL2896; Lopac0_000686; Oprea1_117113; BSPBio_000237; BSPBio_003037; Hydratropic acid, m-benzoyl-; KBioGR_000435; KBioSS_001789; MLS000028446; MLS001201752; MLS001306444; MLS002548889; MLS006011967; BIDD:GT0443; DivK1c_000598; SPECTRUM1501215; SPBio_000952; SPBio_002158; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+-)-; BPBio1_000261; GTPL4795; IDEA-033; Ketoprofen (JP17/USP/INN); Ketoprofen, >=98% (TLC); DTXSID6020771; DKYWVDODHFEZIM-UHFFFAOYSA-; HMS501N20; KBio1_000598; KBio2_001789; KBio2_004357; KBio2_006925; KBio3_002537; (+/-)-m-Benzoylhydratropic acid; NINDS_000598; HMS1568L19; HMS1921B12; HMS2089B16; HMS2092L19; HMS2095L19; HMS2234H16; HMS3259I05; HMS3262I13; HMS3372M08; HMS3373G09; HMS3649N10; HMS3655C15; HMS3712L19; HMS3884K04; Pharmakon1600-01501215; BCP23428; HY-B0227; 2-(3'-benzoylphenyl)propionic acid; 2-(3-benzoylphenyl) propionic acid; alpha(3-benzoylphenyl)propionic acid; Tox21_110594; Tox21_200847; Tox21_500686; (.+/-.)-m-Benzoylhydratropic acid; 2-(3-benzoylphenyl) propionoic acid; alpha-(m-benzoylphenyl)propionic acid; BDBM50022271; CCG-39685; NSC758144; s1645; STL450995; (R)-(-)-Ketoprofen-[13C,d3]; 2-(3-Benzoylphenyl)propanoic acid #; alpha-(3-benzoylphenyl)propionic acid; AKOS007930512; alpha-(m-benzoylphenyl) propionic acid; Tox21_110594_1; 19583RP; AC-1486; BCP9000810; DB01009; Ketoprofen [USAN:USP:INN:BAN:JAN]; KS-5031; LP00686; MCULE-9740144074; NC00459; NSC 758144; RU-4733; SDCCGSBI-0050664.P004; IDI1_000598; (rs)-2-(3-benzoylphenyl)propanoic acid; NCGC00015578-02; NCGC00015578-03; NCGC00015578-04; NCGC00015578-05; NCGC00015578-07; NCGC00015578-08; NCGC00015578-10; NCGC00015578-12; NCGC00015578-23; NCGC00094043-01; NCGC00094043-02; NCGC00094043-03; NCGC00094043-04; NCGC00258401-01; NCGC00261371-01; BK166172; Ketoprofen 100 microg/mL in Acetonitrile; ((c)I)-Ketoprofen-d4(propionic-d4 acid); 3-Benzoyl-.alpha.-methylbenzeneacetic acid; BCP0726000302; SBI-0050664.P003; (+/-)-2-(3-Benzoylphenyl)propionic acid; L''Acide (benzoyl-3-phenyl)-2-propionique; UNM-0000306100; AB00052249; AM20060549; EU-0100686; FT-0602834; FT-0670646; FT-0670647; K0038; Ketoprofen, meets USP testing specifications; Orudis, Profenid, Dexal, Keduril, Ketofen,; R.P. 19583; SW196784-3; BIM-0050664.0001; C01716; D00132; D78110; Ketoprofen, VETRANAL(TM), analytical standard; AB00052249-17; AB00052249-19; AB00052249-20; AB00052249_21; AB00052249_22; 071K154; A815896; Q409192; Q-201268; SR-01000075949-1; SR-01000075949-6; SR-01000075949-9; (.+/-.)-3-Benzoyl-.alpha.-methylbenzeneacetic acid; Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (+/-); BRD-A97739905-001-05-9; BRD-A97739905-001-15-8; SR-01000075949-18; F2173-0960; Z1695709452; Ketoprofen, British Pharmacopoeia (BP) Reference Standard; Ketoprofen, European Pharmacopoeia (EP) Reference Standard; Ketoprofen, United States Pharmacopeia (USP) Reference Standard; N-FMOC-3-AMINO-4-(4-TERT-BUTOXY-PHENYL)-BUTYRICACID; Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material; 154907-35-4
• Indication:
  In total 5 Indication(s)
  Migraine [ICD-11: 8A80]; Approved; [1]
  Musculoskeletal pain [ICD-11: MG30]; Approved; [1]
  Osteoarthritis [ICD-11: FA00-FA05]; Approved; [1]
  Pain [ICD-11: MG30]; Approved; [1]
  Pain [ICD-11: MG30]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Ovarian cancer [ICD-11: 2C73]; [1]
• Target: Prostaglandin G/H synthase 2 (COX-2); PGH2_HUMAN; [1]
• Formula: C16H14O3
• IsoSMILES: CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
• InChI: 1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
• InChIKey: DKYWVDODHFEZIM-UHFFFAOYSA-N
• PubChem CID: 3825
• ChEBI ID: CHEBI:6128
• TTD Drug ID: D0W9WF
• VARIDT ID: DR00690
• INTEDE ID: DR0907
• DrugBank ID: DB01009

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Staphylococcus meningitis [ICD-11: 1B54]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Transmembrane protein 94 (TMEM94) [2]

• Sensitive Disease: Staphylococcus aureus infection [ICD-11: 1B54.0]
• Molecule Alteration: Methylation; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: S. aureus isolates; 41687
• Experiment for Molecule Alteration: PCR; Docking assay
• Experiment for Drug Resistance: Antimicrobial susceptibility testing; Phenotypic assay; MIC assay; Checkerboard microdilution assay
• Mechanism Description: This study aimed to identify the prevalence of erythromycin and erythromycin-induced resistance and assess for potential inhibitors. A total of 99 isolates were purified from various clinical sources. Phenotypic detection of macrolide-lincosamide-streptogramin B (MLSB)-resistance phenotypes was performed by D-test. MLSB-resistance genes were identified using PCR. Different compounds were tested for their effects on erythromycin and inducible clindamycin resistance by broth microdilution and checkerboard microdilution methods. The obtained data were evaluated using docking analysis. Ninety-one isolates were S. aureus. The prevalence of constitutive MLSB, inducible MLSB, and macrolide-streptogramin (MS) phenotypes was 39.6%, 14.3%, and 2.2%, respectively. Genes including ermC, ermA, ermB, msrA, msrB, lnuA, and mphC were found in 82.6%, 5.8%, 7.7%, 3.8%, 3.8%, 13.5%, and 3.8% of isolates, respectively. Erythromycin resistance was significantly reduced by doxorubicin, neomycin, and omeprazole. Quinine, ketoprofen, and fosfomycin combated and reversed erythromycin/clindamycin-induced resistance. This study highlighted the significance of managing antibiotic resistance and overcoming clindamycin treatment failure. Doxorubicin, neomycin, omeprazole, quinine, ketoprofen, and fosfomycin could be potential inhibitors of erythromycin and inducible clindamycin resistance.

ICD-02: Benign/in-situ/malignant neoplasm

Ovarian cancer [ICD-11: 2C73]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ATP-binding cassette sub-family C2 (ABCC2) [1]

• Resistant Disease: Ovarian cancer [ICD-11: 2C73.0]
• Molecule Alteration: Function; Inhibition
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SW48 cells; Colon; Homo sapiens (Human); CVCL_1724
• In Vitro Model: A2780/RCIS cells; Ovary; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Flow cytometric efflux assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: A new series of quinoline analogs of ketoprofen was designed and synthesized as multidrug resistance protein 2 (MRP2) inhibitors using ketoprofen as the lead compounds.

References

• Ref 1: Synthesis and biological evaluation of novel quinoline analogs of ketoprofen as multidrug resistance protein 2 (MRP2) inhibitors .Iran J Basic Med Sci. 2021 Jun;24(6):815-825. doi: 10.22038/ijbms.2021.54554.12265. 10.22038/ijbms.2021.54554.12265
• Ref 2: Inhibition of Erythromycin and Erythromycin-Induced Resistance among Staphylococcus aureus Clinical Isolates. Antibiotics (Basel). 2023 Mar 2;12(3):503.